


Iconographie




Dossier 3 – Question 1




Dossier 27 – Question 15




Dossier 7 – Question 2




Dossier 30 – Question 4




Dossier 8 – Question 2



Dossier 27 – Question 4




Dossier 8 – Question 6




Dossier 22 – Énoncé




Dossier 2 – Question 2




Dossier 11 – Question 4




Dossier 10 – Question 2




Dossier 32 – Question 9




Dossier 19 – Question 8



Dossier 31 – Question 9




Dossier 24 – Question 10




Dossier 13 – Question 2



Dossier 4 – Énoncé




Dossier15 – Question 3




Dossier 25 – Question 3




Dossier 26 – Question 4



Dossier 28 – Question 5




Dossier 11 – Question 13




Dossier 12 – Question 6




Dossier 29 – Question 9




Dossier10 – Question 6




Dossier13 – Question 4




Dossier 25 – Question 5




Dossier 14 – Question 5




Dossier 16 – Question 12



Dossier 24 – Question 11



Dossier 17 – Question 9




Dossier 31 – Question 10



Dossier 25 – Question 6



Dossier 22 – Question 7




Dossier 7–Question 7




Dossier 24 – Question 15



Dossier 23 – Question 3




Dossier 32 – Question 9




Dossier 25 – Question 8




Dossier 26 – Question 10




Dossier 24 – Question 11




Dossier 14 – Question 2




Dossier 12 – Question 7



Dossier 24 – Question 13




Dossier 27 – Question 6



Dossier 25 – Question 3

		LIN	Théo	LSN		Pré	%Th.	Post 1	%Ch
Date visite						03.02.16		03.02.16	
Heure du test						16:03		16:13	
Substance								AIROMIR	
CVF	[L]	2.46	3.47	4.47		2.61	75	2.87	10
VEMS	[L]	1.90	2.73	3.57		0.86	32	1.06	23
VEMS % CVF	[%]	45.61	78.85	112.10		33.06	42	37.01	12
VEMS % CV MAX	[%]	64.08	75.87	87.66		32.88	43	37.01	13
DEP	[L/s]	5.52	7.51	9.50		2.32	31	2.31	-1
DEM 75	[L/s]	3.84	6.66	9.47		0.66	10	0.85	28
DEM 50	[L/s]	1.74	3.91	6.08		0.37	9	0.47	27
DEM 25	[L/s]		1.30	2.59		0.21	16	0.25	19
DEMM 25/75	[L/s]	1.46	3.17	4.88		0.34	11	0.43	27
VIMS	[L]					2.01		2.07	3
DEM 50 % DIM 50	[%]					18.30		22.96	25
Capacité Vitale	[L]	2.67	3.59	4.51		2.60	72	2.87	10
CPT	[L]	4.87	6.02	7.18		7.18	119		
VR	[L]	1.63	2.30	2.98		4.58	199		
CRFpl	[L]	2.33	3.31	4.30		6.05	183		
VRE	[L]	1.01	1.01	1.01		1.47	146		
CI	[L]	2.58	2.58	2.58		1.12	44		
VR % CPT	[%]	29.55	38.53	47.51		63.82	166		


Dossier 24 – Question 13



Dossier 26 – Question 9

Date		Théo	Pré 19/02/16	%Pré/Théo	Post 19/02/16	%Post/Théo
CVF	[L]	4.01	3.00	74.8	3.04	75.7
VEMS	[L]	3.05	2.13	69.8	2.04	66.8
VEMS % CVF	[%]		70.87		66.99	
VEMS % CV MAX	[%]	74.07	64.37	86.9	66.99	90.4
DEMM 25/75	[L/s]	3.01	1.54	51.2	1.44	47.7
DEM 75	[L/s]	7.13	3.51	49.2	2.81	39.4
DEM 50	[L/s]	4.13	2.14	51.8	2.06	49.8
DEM 25	[L/s]	1.41	0.61	43.4	0.76	54.0
DEP	[L/s]	7.94	3.55	44.7	3.24	40.9
VIMS	[L]		1.80		1.92	
DIM 50	[L/s]		1.50		1.52	
CV MAX	[L]	4.16	3.31	79.4	3.04	73.0
VRE	[L]	1.02	0.77	75.0		
CI	[L]	3.14	2.54	80.8		
CRF(Pleth)	[L]	3.73	4.67	125.2		
VR	[L]	2.71	3.90	144.2		
CPT	[L]	7.14	7.21	100.9		
VR % CPT	[%]	42.43	54.16	127.6		

Dossier 24 – Question 5



Dossier 26 – Question 8

I. *Escherichia coli*

Antibiogramme		I
PENICILLINES		
Ampicilline	R	>16
Amoxi+Ac.clavulanique	R	16
Ticarcilline	R	>64
Pipéra+Tazobactam	R	64
CEPHALOSPORINES		
Céfalotine	I	32
Céfoxitine	S	≤4
Céfotaxime	S	≤1
Ceftazidime	S	≤1
CARBAPENEMES		
Imipénème	S	≤0.250
Ertapénème	S	≤0.500
AMINOSIDES		
Gentamicine	S	≤1
Tobramycine	S	≤1
Amikacine	S	≤2
QUINOLONES		
Acide Nalidixique	S	≤2
Ofloxacin	S	≤0.250
Ciprofloxacine	S	≤0.250
SULFAMIDES-TRIMETHOPRIME		
Triméthoprime/sulfaméthoxazole	S	


S:sensible I:intermédiaire R:résistant C:CMI en cours
D:sensibilité diminuée B:Bas Niveau de Résistance H:Haut Niveau de Résistance



Dossier 24 – Question 14



Dossier 4 – Question 3



Dossier 4 – Question 13



Dossier 4 – Question 3

Items traités

N° d'item	Titre de l'item	N° de dossier											
		1	2	3	4	5	6	7	8	9	10	11	12
Item 73	Addiction au tabac	x											x
Item 108	Troubles du sommeil de l'adulte					x							
Item 132	Thérapeutiques antalgiques, médicamenteuses et non médicamenteuses								x				
Item 147	Otites infectieuses de l'adulte et de l'enfant												
Item 151	Infections broncho-pulmonaires communautaires de l'adulte		x									x	
Item 154	Septicémie/Bactériémie/Fongémie de l'adulte et de l'enfant											x	
Item 155	Tuberculose												
Item 159	Coqueluche									x			
Item 162	Grippe												
Item 180	Accidents du travail et maladies professionnelles : maladies respiratoires d'origine professionnelle										x		
Item 182	Hypersensibilités et allergies chez l'enfant et l'adulte												
Item 184	Asthme, rhinite												
Item 188	Pathologies auto-immunes												
Item 199	Dyspnée aiguë et chronique												x
Item 200	Toux chronique de l'adulte												
Item 201	Hémoptysie												
Item 202	Epanchement pleural								x		x		
Item 203	Opacités et masses intrathoraciques chez l'enfant et l'adulte				x								
Item 204	Insuffisance Respiratoire Chronique	x											
Item 205	Bronchopneumopathie Chronique Obstructive	x											
Item 206	Pneumopathies Interstitielles Diffuses							x					x
Item 207	Sarcoidose			x									
Item 222	Hypertension artérielle pulmonaire												
Item 224	Embolie pulmonaire et thrombose veineuse profonde						x					x	
Item 228	Orientation diagnostique devant une douleur thoracique aiguë et chronique												
Item 326	Prescription et surveillance des classes médicamenteuses les plus courantes chez l'adulte et chez l'enfant			x			x						
Item 306	Tumeurs du poumon, primitives et secondaires				x						x		
Item 333	Cœdème de Quincke et anaphylaxie												
Item 354	Détresse Respiratoire de l'adulte	x						x					
Item 356	Orientation diagnostique et conduite à tenir devant un pneumothorax												
Item 329	Prise en charge immédiate, évaluation des complications précoces chez un traumatisé thoracique								x				

